Berberine Modulates RXRα/PPARγ/NEDD4 to Suppress SASP in Atherosclerosis

Study Background and Research Question

Chronic inflammation is a hallmark of age-related diseases, notably atherosclerosis, where the accumulation of senescent cells contributes to persistent tissue dysfunction. Senescent cells release a diverse array of pro-inflammatory cytokines, chemokines, and matrix-remodeling factors known as the senescence-associated secretory phenotype (SASP), which drives local and systemic inflammatory responses. Recent single-cell sequencing analyses of human carotid plaques have demonstrated a predominance of aging foam cells, implicating their role in sustaining inflamed vascular microenvironments. While berberine (BBR), a plant-derived isoquinoline alkaloid, has been reported to attenuate cellular senescence, the molecular mechanisms underpinning its effects in atherosclerotic contexts remained unclear. This study specifically investigated how BBR influences SASP-related inflammation through the RXRα/PPARγ/NEDD4 signaling axis in macrophage-derived foam cells (see internal summary).

Key Innovation from the Reference Study

The central innovation of this research lies in the identification of a distinct molecular pathway by which BBR mitigates SASP-driven inflammation in atherosclerosis. The study demonstrates that BBR activates the RXRα/PPARγ heterodimer, leading to upregulation of NEDD4, an E3 ubiquitin ligase. This pathway enhances the ubiquitination and subsequent degradation of the GATA4/p62 complex, a crucial driver of SASP-associated protein production in macrophage-derived foam cells. By directly linking BBR’s anti-inflammatory activity to the modulation of the RXRα/PPARγ/NEDD4 cascade, the research highlights a new mechanistic target for addressing chronic vascular inflammation and age-related disease progression (related article).

Methods and Experimental Design Insights

The study employed a multifaceted approach combining in vivo and in vitro techniques:

• Animal Models: ApoE^-/- mice, known for their susceptibility to atherosclerosis, were used and fed a high-fat diet to induce plaque formation. BBR was administered to assess its effects on plaque morphology and systemic inflammation.
• Cellular Models: Macrophage-derived foam cells were generated using peritoneal macrophages and RAW264.7 cells. These cells were exposed to BBR, and SASP-related protein expression was quantified.
• Pathway Interrogation: Smart-seq transcriptomic profiling was used to map BBR-responsive pathways. Lentiviral-mediated knockdown of RXRα in macrophages enabled the assessment of pathway dependency in vivo.
• Protein and Gene Analysis: Western blotting, qPCR, and immunoprecipitation were performed to examine the activation states of RXRα, PPARγ, NEDD4, and their downstream targets, including GATA4 and p62.
• Ubiquitination Assays: Ubiquitin-mediated degradation of the GATA4/p62 complex was assessed following BBR treatment, with particular attention to the impact on SASP cytokine production.

Core Findings and Why They Matter

Key findings from the study include:

• BBR significantly reduced the expression of SASP-associated inflammatory proteins in both RAW264.7 and primary macrophage-derived foam cells.
• Transcriptomic and biochemical analyses revealed that BBR treatment activated the RXRα/PPARγ heterodimer, which in turn upregulated NEDD4 transcription.
• The increase in NEDD4 promoted ubiquitination and proteasomal degradation of the GATA4/p62 complex, thereby suppressing the production of SASP proteins.
• Importantly, knockdown of RXRα in macrophages abrogated the anti-inflammatory effects of BBR, confirming the pathway's essential role in mediating these responses.

These results demonstrate a direct mechanistic link between BBR and the modulation of SASP-driven vascular inflammation via the RXRα/PPARγ/NEDD4 axis. The repression of SASP factors has important implications for slowing atherosclerosis progression and possibly other age-related inflammatory pathologies (internal article). The ability to manipulate this pathway offers a targeted strategy for research into vascular aging and chronic disease.

Comparison with Existing Internal Articles

Several internal reviews and article summaries corroborate the mechanistic insights presented here. For instance, the article "Berberine Attenuates SASP Inflammation via RXRα/PPARγ/NEDD4 in Atherosclerosis" reinforces the central finding that BBR suppresses SASP-driven inflammation through coordinated activation of this signaling axis. Another summary highlights the translational potential for targeting vascular aging by manipulating components of the RXRα/PPARγ pathway. Notably, these internal resources emphasize the specificity of the RXRα/PPARγ/NEDD4 axis in macrophage-driven inflammation, without extending the mechanism to unrelated disease domains. This consistency across sources increases confidence in the validity of the reference study’s mechanistic claims.

Limitations and Transferability

While the study provides compelling evidence for the RXRα/PPARγ/NEDD4 pathway’s role in SASP modulation and atherosclerosis, several limitations warrant consideration:

• Animal Model Specificity: The primary in vivo evidence derives from ApoE^-/- mice, which, while well-established for atherosclerosis research, may not fully capture the human disease spectrum.
• Cell Line Constraints: Although primary macrophages and RAW264.7 cells are relevant, human macrophage studies would strengthen translational prospects.
• Pathway Complexity: The RXRα/PPARγ/NEDD4 axis is embedded in a broader signaling network. Off-target effects or compensatory mechanisms may emerge in other cell types or disease contexts.
• Lack of Clinical Data: The translational applicability to human patients remains to be established, especially regarding the safety and efficacy of targeting this pathway therapeutically.

Overall, while the findings are robust within the context of atherosclerosis and macrophage biology, caution is warranted in extrapolating to other chronic inflammatory or age-associated diseases until further studies are available.

Protocol Parameters

• BBR administration in ApoE^-/- mice: High-fat diet for atherosclerosis induction, followed by BBR dosing (parameters as per reference study) to assess plaque and inflammatory marker changes.
• Macrophage-derived foam cell preparation: Peritoneal macrophages isolated and differentiated with ox-LDL to induce foam cell phenotype prior to BBR treatment.
• Lentiviral RXRα knockdown: Macrophage-specific RXRα silencing using pLVCD68-shRNA constructs in vivo to evaluate pathway dependency.
• Smart-seq transcriptomic profiling: Used to identify pathway activation and downstream targets following BBR intervention.
• SASP protein quantification: Western blot and ELISA for cytokine, chemokine, and matrix protease expression in cell lysates and culture supernatants.

Research Support Resources

For researchers aiming to dissect the role of PPARγ signaling in macrophage biology or atherosclerosis models, selective chemical tools are crucial. T0070907 (SKU A4301) is a well-characterized PPARγ antagonist with nanomolar affinity, enabling precise inhibition of PPARγ function in vitro and in vivo. Its established selectivity profile allows for targeted interrogation of PPARγ-dependent events, such as those seen in the RXRα/PPARγ/NEDD4 axis described above. According to the product information, T0070907 is suitable for studies on adipogenesis inhibition, cell cycle G2/M arrest, and PPARγ/RXRα heterodimer modulation. Researchers can incorporate this tool in parallel with genetic approaches to clarify the specific contributions of PPARγ antagonism in inflammation and vascular aging workflows.